Faruqi & Faruqi Launches Investigation into LifeMD Investors' Claims Ahead of Deadline

Investigation of LifeMD by Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP, a prominent national securities law firm, has announced its investigation into possible claims against LifeMD, Inc. (NASDAQ: LFMD). The firm's Securities Litigation Partner, James (Josh) Wilson, is reaching out to investors who may have suffered losses exceeding $75,000 between May 7 and August 5, 2025. This move is part of their commitment to protect investors' rights and ensure accountability in the financial markets.

The investigation comes in light of serious allegations against LifeMD and its executives, who are accused of violating federal securities laws. The firm's inquiry suggests that LifeMD made false or misleading statements about its competitive position, which significantly misrepresented the company's outlook to its investors.

Key Allegations

The complaint against LifeMD argues that:
1. Overstated Competitive Position: LifeMD allegedly exaggerated its market competitiveness, which can mislead investors about the company's prospects.
2. Mismanagement of Financial Guidance: The company’s inflated revenue forecasts did not reflect actual business conditions, particularly in the context of rising acquisition costs related to their drug offerings, such as those targeting obesity.
3. Misinformation on Business Operations: By failing to provide a realistic appraisal of its operational challenges and growth potential, LifeMD's executives misled investors, leading to unwarranted financial risk.

On August 5, 2025, LifeMD disclosed its second-quarter financial results, significantly revising its revenue guidance, predicting total revenues of only $250 to $255 million, down from earlier estimates of $268 to $275 million. This news led to a drastic 44.8% decline in LifeMD's stock on August 6.

The Role of Lead Plaintiff

In a federal securities class action, the lead plaintiff is usually the investor who has suffered the most significant financial loss and is able to adequately represent the interests of other investors in the class. The firm emphasizes that any member of the affected group can pursue the role of the lead plaintiff or remain an absent member of the class without compromising their right to financial recovery.

For investors wishing to join the investigation, Faruqi & Faruqi, LLP encourages contacting them directly. Interested parties, including whistleblowers and former employees, are also invited to provide information regarding LifeMD's business practices.

Timely Action is Required

Investors must act promptly, as the deadline to seek lead plaintiff status is October 27, 2025. Those with relevant claims or information can reach out to Josh Wilson at Faruqi & Faruqi, LLP at 877-247-4292 or 212-983-9330 (Ext. 1310). More information on the ongoing class action and further developments can be found on the firm's website.

Commitment to Investor Rights

Established in 1995, Faruqi & Faruqi, LLP has successfully recovered hundreds of millions of dollars for investors over the years. Their proactive investigations underscore their dedication to advocating for shareholders' rights against corporate malfeasance. Investors affected by LifeMD's actions are strongly encouraged to explore their legal options to seek redress and protect their investments.

Stay informed about the latest updates in this case and other similar inquiries by following Faruqi & Faruqi on their social media channels, including LinkedIn, X, and Facebook. For those affected by recent financial news, now is the time to act.

For more details on this investigation or to understand your rights as an investor in LifeMD, please visit Faruqi & Faruqi's website.